In proposed work, Bilayer tablets of an antidiabetes agent: Metformin, Glimepiride and Pioglitazone hydrochloride is to formulate, and evaluate for oral sustained drug release, in pharmaceutical system to enhance its oral bioavailability, Reduction in drug toxicity, Reduction in dosing frequency of drug. Biphasic release is characterized by rapid initial release of the drug, followed by sustained rate of release. The drug released by the initial pulse, quickly attains the therapeutic plasma drug levels and ameliorates the slow onset of action of sustained release layer (approx. 60 min). This increases patient compliance as the patient is quickly relief. Such type of drug delivery systems is designed to deliver the drug in such a way that the drug level is maintained within the therapeutic window for a period as long as the system continues to deliver the drug and to avoid fluctuations in plasma drug level.
The two principal defects in type 2 diabetes are insulin deficiency and insulin resistance. Therefore, combining an insulin-providing agent with an insulin sensitizing agent will augment the efficacy of current anti- hyperglycaemic agents. This is the rational for the development of Glimepiride, Metformin and Pioglitazone combination. The ultimate or primary goal of therapy for type 2 diabetes is to prevent the mortality and morbidity related to the microvascular and macrovascular complications. It is increasingly obvious that to achieve this on a global perspective will have to identify better and more effective treatment strategies to maintain tight glycemic control.
Administration of Metformin, Glimepiride and Pioglitazone combination is used for reducing the Oxidative stress-induce nuclear damage & Reproductive toxicity.